http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Woong Youn ),( Tae Yoon Kim ),( Byung Soo Kim ),( Seung Chul Lee ),( Jeung Hoon Lee ),( Yong-beom Choe ),( Joo-heung Lee ),( Jee-ho Choi ),( Joo Young Roh ),( Seong Jin Jo ),( Eun-so Lee ),( Mi 대한피부과학회 2018 대한피부과학회 학술발표대회집 Vol.70 No.2
Background: The Phase Ⅲ studies, VOYAGE 1 and 2, were conducted to assess guselkumab for the treatment of patients with moderate to severe psoriasis. However, these studies included a worldwide study population. Objectives: To determine the efficacy and safety of guselkumab in Korean patients. Methods: This analysis included 28 patients from VOYAGE 1 and 98 patients from VOYAGE 2. In total, 126 patients were analyzed. Outcomes through week 28 were analyzed due to differences in design after week28. Results: Of 126 Korean patients randomized, 30 received placebo, 63 were assigned to guselkumab, and 33 received adalimumab. Guselkumab was superior to adalimumab in achieving an IGA 0 score (clear skin) at week 12 (31.7% vs 0.0%, p<0.001) and at week 24 (52.4% vs 21.2%, p=0.004), respectively. Among patients treated with guselkumab, 40 of 63 (63.5%) achieved a PASI75 response at week 8; at week 24, a significantly higher proportion of guselkumab patients achieved a PASI 75 compared to adalimumab patients (93.7% vs 66.7%, respectively, p<0.001). In addition, higher proportions of guselkumab patients achieved PASI 90 and PASI 100 than adalimumab patients at week 24 (PASI90; 73.0% vs 57.6%, p=0.168 / PASI100; 20.6% vs 15.2%, p=0.591, respectively). Through week 28, guselkumab and adalimumab showed comparable safety profiles. Conclusion: The efficacy and safety of guselkumab in Korean psoriasis patients through 28 weeks was consistent with findings reported for the VOYAGE1 and 2 trials.
지미정,정지웅,이종혁,Mi Jung Chi,Jee Woong Jeung,Jong Hyeok Lee 대한안과학회 2006 대한안과학회지 Vol.47 No.7
Purpose: BioSorbFX?(BIONX Implant Inc.) and Macropore?(Medtronics Inc.) are mesh-type resorbable copolymer plate. This report presents a new model necessary for orbital wall reconstruction, accoding to the operative outcomes of orbital fracture with its use. Methods: A follow-up on 11 patients was performed to ascertain the operative effects of the mesh-type resorbable material for 6 months. Results: The patients were 7 males and 4 females. The patients` average age was 29.7 years and the mean follow-up period was 8.1 months. The most common site of fracture was inferior wall. In these cases, simultaneous fracture of the medial wall and floor was frequently observed. One case showed limitation of ocular movement, diplopias and enophthalmos simultaneously; 3 cases, enophthalmos and diplopia; 5 cases showed limitation of ocular movement and diplopia; and 2 cases, considerable possibility or the presence of enophthalmos due to extended fracture size. The cases improved remarkably after being operated and none were observed to have worsened. Moreover, serious complications, such as visual loss, the infection of implants, dislocation, exposure, etc., were not observed. Conclusions: Altogether, it is considered that the mesh-type resorbable copolymer plate may be safely used in orbital wall reconstruction without conspicuous complication.